SGLT-2 inhibitor

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic Syndrome

SGLT-2 Inhibitors in the Treatment of Ascites

Adiponectin in Patients With Metabolic Disorders

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers

Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)

The Use of Advanced Imaging in HFpEF

Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3

SGLT2 Inhibitors and Renal Anemia in Japan: RWD

GLP1 Analogues and the Risk of Osteoarthritis

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Effect of SGLT2 Inhibitors on Anemic CKD Patients

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

EFFECT OF HYBRID CLOSED-LOOP SYSTEMS ON CARDIOVASCULAR MARKERS IN TYPE 1 DIABETES.

Initiation of ARNi and SGLT2i in Patients With HFrEF